Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Long term efficacy and safety in children and young adults with treatment resistant epilepsy treated with Cannabidiol

Trial Profile

Long term efficacy and safety in children and young adults with treatment resistant epilepsy treated with Cannabidiol

Status: Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 23 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cannabidiol (Primary)
  • Indications Epilepsy; Seizures
  • Focus Adverse reactions; Expanded access; Therapeutic Use
  • Most Recent Events

    • 20 Dec 2022 Results(4-year results) assessing Long-term efficacy and safety of cannabidiol in patients with treatment-resistant epilepsies through January 2019 published in the Epilepsia
    • 22 Apr 2021 Results Evaluating the effect of CBD on convulsive (clonic, tonic, tonic-clonic, atonic, focal to bilateral tonic-clonic) and nonconvulsive (focal, absence, myoclonic, myoclonic-absence, spasms) seizures and safety in patients with TREs in the EAP presented at the 73rd Annual Meeting of the American Academy of Neurology
    • 13 Apr 2021 According to a GW Pharmaceuticals media release, results of this trial will be presented at the 2021 American Academy of Neurology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top